CTSO logo

CYTOSORBENTS CORP

CTSONASDAQ
πŸ† #4674 by market capEarnings Mar 24US Equity
$4.16β–Ό $0.97 (βˆ’18.91%)
Market closed Β· at close
πŸ””
Track CTSO
Get earnings, price moves & breaking news on Telegram
Track
24hβ–Ό 18.9%
7dβ–Ό 24.4%
14dβ–Ό 8.8%
30dβ–Ό 22.5%
ytdβ–Ό 66.8%
1yβ–Ό 70.3%
🏦Market Cap
$13M
Small Cap
πŸ“ˆRevenue Growth (YoY)
8.6%
Slowing
πŸ“ŠGross Margin
71.6%
High
πŸ’΅FCF Margin
β€”
βš–οΈP/S Ratio
0.4x
Cheap
Otter Score
β€”
Insufficient data

Trading Snapshot

Day Range
$4.16 – $4.79
52-Week Range
$2.84 – $17.00
Volume (shares)
28,812
Avg Volume (shares)
β€”
Shares Outstanding
3.1M
Next Earnings
2027-03-24

Fundamentals Snapshot

Annual Revenue
$37M
Last Q Revenue
$10M
P/E Ratio
β€”
P/S Ratio
0.4x
EPS (TTM)
$-4.84
Dividend Yield
β€”
Dilution (1yr)
+14.8%
CTSO logo

CYTOSORBENTS CORP

CTSO
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$37Mβ–² +4.1% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
71.5%β–² +2.2% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$14Mβ–Ό βˆ’13.5% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$13Mβ–Ό βˆ’14.8% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
3.1Mβ–² +14.8% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
βˆ’$23Mβ–² +$751K YoY
StockOtter Β· stockotter.space

About CYTOSORBENTS CORP

Cytosorbents Corporation specializes in creating and bringing to market innovative medical devices. Their core expertise lies in a unique blood purification platform, built upon a proprietary adsorbent and porous polymer technology. The company's leading product, CytoSorb, is an extracorporeal filter designed to remove cytokines from the blood. It serves as a complementary treatment in various critical care scenarios, including sepsis, managing complications during and after heart bypass surgery, and improving the viability of donor organs for transplantation. Beyond CytoSorb, Cytosorbents offers a portfolio of specialized devices. These include VetResQ, used to assist in treating critical conditions like sepsis and pancreatitis in animals; CytoSorb-XL, another device targeting sepsis and other severe illnesses; HemoDefend, a platform for purifying blood supplies by removing contaminants that cause transfusion reactions and diseases, as well as anti-A and anti-B antibodies from blood products; K+ontrol, designed for patients with severe, life-threatening hyperkalemia; and ContrastSorb, which extracts intravenous contrast agents following imaging procedures (like CT scans, angiograms, or interventional radiology) to mitigate the risk of contrast-induced kidney damage. The company is also actively developing several new solutions: BetaSorb, aimed at preventing and treating complications from metabolic toxin buildup in chronic kidney disease patients; DrugSorb, which focuses on eliminating harmful chemicals from the bloodstream; and DrugSorb-ATR, an innovative system for removing antithrombotic agents. Originally established as MedaSorb Technologies Corporation in 1997, the company adopted its current name, Cytosorbents Corporation, in May 2010. Its corporate headquarters are situated in Princeton, New Jersey.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Insufficient data
β€”/100
Analyst data unavailable.

Latest News & Updates

PRNewsWireΒ·2d ago

CytoSorbents Announces $6.25 Million Common Stock Financing Priced At-the-Market under Nasdaq Rules and Concurrent Restructuring of Avenue Capital Credit Facility

$4.0 million registered direct offering of common stock, led by existing shareholders and management $2.25 million of Avenue debt satisfied through the issuance of common stock at the same offering price Total debt reduc

Seeking AlphaΒ·10d ago

Cytosorbents Corporation (CTSO) Q3 2026 Earnings Call Transcript

Cytosorbents Corporation (CTSO) Q3 2026 Earnings Call Transcript

PRNewsWireΒ·10d ago

CytoSorbents Reports Third Quarter 2026 Financial Results, Achieves Operating Cash Flow Breakeven, and Provides Business and Regulatory Update

Delivering on the First of Four Distinct Value Drivers PRINCETON, N.J., Nov. 12, 2026 /PRNewswire/ -- CytoSorbents CorporationΒ (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive car

PRNewsWireΒ·13d ago

CytoSorbents to Participate at the 2026 Jefferies Global Healthcare Conference in London

PRINCETON, N.J., Nov. 9, 2026 /PRNewswire/ -- CytoSorbents CorporationΒ (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, tod

PRNewsWireΒ·24d ago

CytoSorbents to Report Third Quarter 2026 Financial Results and Recent Business Highlights

PRINCETON, N.J., Oct. 29, 2026 /PRNewswire/ -- CytoSorbents CorporationΒ (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, wi

Defense WorldΒ·Oct 11

Cytosorbents (NASDAQ:CTSO) versus Electromed (NYSE:ELMD) Head to Head Comparison

Cytosorbents (NASDAQ: CTSO - Get Free Report) and Electromed (NYSE: ELMD - Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the stre